Physician profile
Donna Allison
NPI 1578533923
$3,454.97
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,158 · 2022: $1,337 · 2023: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.42 | 2021-2023 | |
| Janssen Biotech, INC. | $395.23 | 2021-2022 | |
| Amgen INC. | $341.25 | 2021-2023 | Prolia, Evenity |
| Ucb, INC. | $291.74 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $275.14 | 2021-2022 | |
| Lilly USA, LLC | $233.09 | 2021-2023 | Emgality, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $148.28 | 2021-2023 | Breztri, Bevespi Aerosphere |
| Novartis Pharmaceuticals Corporation | $130.81 | 2021-2023 | |
| Pfizer INC. | $117.39 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $80.72 | 2023 | Orencia |
| Paratek Pharmaceuticals, INC. | $79.92 | 2022-2023 | Nuzyra |
| Novo Nordisk INC | $76.04 | 2023 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $71.73 | 2021-2022 | |
| Antares Pharma, INC. | $67.31 | 2023 | Nocdurna, Xyosted, Tlando |
| Glaxosmithkline, LLC. | $54.82 | 2021-2023 | Trelegy Ellipta |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.